Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc.ABOS · Entity 6281 | Director · Chief Executive Officer | January 21, 2026 | January 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acumen Pharmaceuticals, Inc.
Report date January 21, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 881,275 |
Ending reported balance
After 2026-01-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-21 · Sale · Disposed 9,346 · Balance 883,964 F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024. F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7600 to $1.8800. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-01-22 · Sale · Disposed 2,689 · Balance 881,275 F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024. F3: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.8700 to $1.9000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024.
F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7600 to $1.8800. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.8700 to $1.9000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2026 Filed Jan 23, 2026 18:10 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 2,689 | $1.88 | $5,065.54 |
DisclosureSEC source: 0001628280-26-003346 · wk-form4_1769209845.xml · nonDerivative · entry 2 OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 881,275 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.8700 to $1.9000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:10 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 9,346 | $1.81 | $16,927.48 |
DisclosureSEC source: 0001628280-26-003346 · wk-form4_1769209845.xml · nonDerivative · entry 1 OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 883,964 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7600 to $1.8800. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 18:32 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001628280-26-002962 · wk-form4_1769038356.xml · derivative · entry 2 OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2036-01-20 F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 18:32 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 299,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-002962 · wk-form4_1769038356.xml · nonDerivative · entry 1 OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 893,310 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 18:50 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 5,388 | $1.73 | $9,306.69 |
DisclosureSEC source: 0001628280-26-001895 · wk-form4_1768261820.xml · nonDerivative · entry 3 OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 593,510 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 27, 2025. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.6700 to $1.8400. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 18:50 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 12,941 | $1.76 | $22,831.81 |
DisclosureSEC source: 0001628280-26-001895 · wk-form4_1768261820.xml · nonDerivative · entry 2 OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 598,898 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 27, 2025. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7100 to $1.8100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 18:50 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 8,143 | $1.82 | $14,815.37 |
DisclosureSEC source: 0001628280-26-001895 · wk-form4_1768261820.xml · nonDerivative · entry 1 OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611,839 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 27, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2026 Filed Jan 7, 2026 21:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 37,755 | $1.99 | $74,981.43 |
DisclosureSEC source: 0001628280-26-001263 · wk-form4_1767839464.xml · nonDerivative · entry 3 OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 619,982 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9500 to $2.0300. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 21:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 5,102 | $1.97 | $10,031.55 |
DisclosureSEC source: 0001628280-26-001263 · wk-form4_1767839464.xml · nonDerivative · entry 2 OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 657,737 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $2.0000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 4,649 | $1.97 | $9,163.18 |
DisclosureSEC source: 0001628280-26-001263 · wk-form4_1767839464.xml · nonDerivative · entry 1 OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 662,839 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9000 to $2.0600. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 17:18 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 12,619 | $1.59 | $20,102.07 |
DisclosureSEC source: 0001576885-25-000035 · wk-form4_1737670677.xml · nonDerivative · entry 1 OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 667,488 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.5700 to $1.6100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 20:09 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 338,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001576885-25-000021 · wk-form4_1736298537.xml · derivative · entry 3 OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 338,000 Underlying: Common Stock · 338,000 shares Expires 2035-01-07 F4 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 20:09 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 225,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001576885-25-000021 · wk-form4_1736298537.xml · nonDerivative · entry 2 OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 680,107 F3 · shares: Represents an RSU award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 20:09 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 47,778 | $1.84 | $87,873.30 |
DisclosureSEC source: 0001576885-25-000021 · wk-form4_1736298537.xml · nonDerivative · entry 1 OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 454,707 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7772 to $1.9150. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2024 Filed Jan 19, 2024 19:07 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 15,200 | $3.47 | $52,753.12 |
DisclosureSEC source: 0001576885-24-000029 · wk-form4_1705709243.xml · nonDerivative · entry 1 OConnell Daniel Joseph · CIK 0001865136 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 502,485 F1 · shares: Represents the number of shares sold by the Reporting Person in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2023. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.3950 to $3.6500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:18 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 602,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001576885-24-000009 · wk-form4_1704403087.xml · derivative · entry 2 OConnell Daniel Joseph · CIK 0001865136 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,000 Underlying: Common Stock · 602,000 shares Expires 2034-01-01 F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:18 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 401,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001576885-24-000009 · wk-form4_1704403087.xml · nonDerivative · entry 1 OConnell Daniel Joseph · CIK 0001865136 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 517,685 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 16:22 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 472,500 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001209191-23-003741 · doc4.xml · derivative · entry 2 OConnell Daniel Joseph · CIK 0001865136 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,500 Underlying: Common Stock · 472,500 shares Expires 2033-01-16 F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 16:22 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 114,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003741 · doc4.xml · nonDerivative · entry 1 OConnell Daniel Joseph · CIK 0001865136 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,685 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 16:20 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 455,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-22-004419 · doc4.xml · derivative · entry 1 OConnell Daniel Joseph · CIK 0001865136 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,000 Underlying: Common Stock · 455,000 shares Expires 2032-01-19 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on January 19, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest and become exercisable each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 16:41 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,118 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001209191-21-067613 · doc4.xml · derivative · entry 2 OConnell Daniel Joseph · CIK 0001865136 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,118 shares Expires 2021-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 16:41 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionCommon Stock | 1,118 | $4.47 | $4,997.46 |
DisclosureSEC source: 0001209191-21-067613 · doc4.xml · nonDerivative · entry 1 OConnell Daniel Joseph · CIK 0001865136 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:16 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionWarrant (Right to Buy) · Derivative | 35 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001209191-21-046029 · doc4.xml · derivative · entry 5 OConnell Daniel Joseph · CIK 0001865136 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:16 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionSeries A Preferred Stock · Derivative | 123 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046029 · doc4.xml · derivative · entry 4 OConnell Daniel Joseph · CIK 0001865136 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 123 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 6, 2021, each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · price: On July 6, 2021, each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On July 6, 2021, each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On July 6, 2021, each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:16 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Tax withholdingCommon Stock | 10 | $16.00 | $160.00 |
DisclosureSEC source: 0001209191-21-046029 · doc4.xml · nonDerivative · entry 3 OConnell Daniel Joseph · CIK 0001865136 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,567 F2 · kind: On July 6, 2021, the reporting person exercised a warrant to purchase 35 shares of ABOS common stock for $4.47 a share. The reporting person paid the exercise price on a cashless basis, resulting in ABOS's withholding of 10 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 25 shares. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:16 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | OtherCommon Stock | 35 | $4.47 | $156.45 |
DisclosureSEC source: 0001209191-21-046029 · doc4.xml · nonDerivative · entry 2 OConnell Daniel Joseph · CIK 0001865136 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,577 Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:16 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionCommon Stock | 123 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046029 · doc4.xml · nonDerivative · entry 1 OConnell Daniel Joseph · CIK 0001865136 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 6, 2021, each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.